Lindsay, Vice President at Benvenue Medical, Inc. .. Anchor announces rapid progress in OMJPI collaboration for developing GPCR therapeutic compounds Anchor Therapeutics today announced that it offers successfully completed the first stage of its collaboration and permit agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. . This achievement represents rapid progress for the collaboration, which was released in September 2010 to develop G protein coupled receptor -targeted therapeutic substances making use of Anchor’s proprietary pepducin technology. KlegermanExpanded use for IntelliCap with further CE Tag for aspiration of fluidsUnder the agreement, Anchor and OMJPI function jointly to discover and optimize preclinical advancement candidates against GPCR targets in oncology and metabolic disorders.Reuters: Government Problems Medicare Advantage Suggestions The Obama administration on Friday issued 2013 payment and policy suggestions for U.S. Health insurers that take part in the Medicare Advantage program, saying the proposed changes would bring lower premiums and steady or improved benefits. But the documents did not include an official preliminary estimate for the web average %age modify in reimbursements, departing insurers and financial markets at night about the recommendations’ potential impact on the industry . CQ HealthBeat: CMS: Development Toward Low Premiums, Steady Benefits To Continue Relatively low superior charges and steady benefits have been a hallmark of the personal healthcare plans and prescription medication programs in the Medicare program of late, and that trend shall continue, federal officials said Friday.